School of Medicine


Showing 1-8 of 8 Results

  • Kenneth Mahaffey

    Kenneth Mahaffey

    Professor of Medicine (Cardiovascular Medicine) at the Stanford University Medical Center

    Bio Clinical Focus: Cardiovascular Medicine

    Research Focus:

    My primary research interest is the design and conduct of multicenter clinical trials and analyses of important clinical cardiac issues using large patient databases. My research focuses on novel anticoagulation agents for the treatment of acute coronary syndromes and atrial fibrillation, the study of agents targeted to protect the myocardium during reperfusion therapy for acute myocardial infarction, and the evaluation of cardiovascular safety of diabetic therapies. I am also interested in the methodology of clinical trials. Current research activities include standardization of the definition of myocardial infarction used in clinical trials, the adjudication of suspected clinical endpoint events by Clinical Event Committees (CEC), and the efficient operational conduct of large multinational clinical trials.

    Administrative Focus: Vice Chair of Clinical Research in the Department of Medicine and Member of the Stanford IRB

    Professional Training:

    1985 Stanford University, BS Chemistry
    1989 University of Washington, MD
    1993 University of Arizona, Internship/Residency/Chief Residency
    1996 Duke University, Fellowship in Cardiology
    1996 Duke University, Faculty in Cardiology
    2013 Stanford University, Vice Chair of Clinical Research, Department of Medicine

  • Anurag Mairal

    Anurag Mairal

    Academic Staff - Hourly - CSL, Medicine - Cardiovascular Medicine

    Bio Dr. Anurag Mairal is a Consulting Associate Professor of Medicine and the Director, Global Exchange Program at Stanford Byers Center for Biodesign, Stanford University. In these roles, he leads initiatives focused on applying the biodesign process to resource-constrained settings globally. Further, he facilitates opportunities for students, faculty and fellows at Stanford to work on global healthcare needs. He is part of the founding faculty team for BIOE 371, Global Biodesign: Medical Technology in an International Context, a graduate-level course offered to engineering, business, and medical students at Stanford University. He also has additional appointments as an Adjunct Professor at Stanford Graduate School of Business and Faculty Fellow at the Center for Innovation in Global Health. As a Co-Director of the India Biodesign Phase II initiative, he leads the Forum, a platform for supporting India's medtech entrepreneurs. As the Chair of a BME IDEA APAC, a new initiative to bring together medtech innovation programs in Asia Pacific region, he is focused on building a sustainable organization that supports the needs of innovation stakeholders in the region. Earlier, he served as Associate Director for the Stanford-India Biodesign and Singapore-Stanford Biodesign programs. Concurrently, he is a co-founder and Executive Vice President of Orbees Medical, a SF Bay Area-based strategy consulting firm serving global healthcare industry, with a focus on medtech, pharmaceutical, and digital health industry.

    Dr. Mairal has an extensive background in medical technology development and commercialization, collaborating with partners in the U.S., India, China, and other emerging markets to advance product development, manufacturing, and distribution. Recently, he took two years off from Orbees Medical to take a senior leadership role at PATH, a major global health nonprofit based in Seattle. In this role, he oversaw research and development, commercialization, and implementation of technologies in PATH's medical devices, diagnostics, and digital health divisions. Previously, he held several positions at Johnson & Johnson, including Business Development Director and Product Director for structural heart, cardiology, and peripheral vascular products at Cordis. Before joining J&J, he was a Group Leader and a Process Development Manager at Membrane Technology and Research (MTR). At MTR, he was responsible for business development, strategic alliances, and product development in the bioseparations area. An active mentor to entrepreneurs and industry professionals, he serves on the boards of several for-profit and non-profit organizations and is a Charter Member at EPPIC Global Network.

    Dr. Mairal earned a PhD in chemical engineering from the University of Colorado at Boulder and an MBA from the University of California at Berkeley. He also holds an MS in chemical engineering from the Indian Institution of Technology in Mumbai and a BS in chemical engineering from National Institute of Technology, Raipur. Dr. Mairal was a post-doctoral fellow at the University of Twente, Netherlands and at University of Michigan, Ann Arbor. Dr. Mairal has an MBA from the Haas School of Business at University of California, Berkeley. At Haas, he was a founding co-Chairman of the South Asia Business Conference and Chair of the Biotech Panel for the Asia Business Conference. His work has been published in more than 30 publications, and he has been issued seven patents.

  • Joshua Makower

    Joshua Makower

    Academic Staff - Hourly - CSL, Medicine - Cardiovascular Medicine

    Current Research and Scholarly Interests Dr. Josh Makower serves on the faculty of the Stanford University Medical School as an Adjunct Professor of Medicine and is Co-Founder of Stanford’s Biodesign Innovation Program (now called the Byers Center for Biodesign). Josh helped create the fundamental structure of the Center’s core curriculum and is the chief architect of what is now called “The Biodesign Process.” Over the past 18 years since Josh and Dr. Paul Yock founded the Stanford Biodesign Innovation Program, this curriculum and the associated textbook has been used at Stanford and across the world to train thousands of students, faculty and industry leaders on the biodesign process towards the advancement of medical innovation for the improvement of patient care. Josh has practiced these same techniques directly as the Founder & Executive Chairman of ExploraMed, a medical device incubator, creating 8 companies since 1995. Transactions from the ExploraMed portfolio include NeoTract, acquired by Teleflex, Acclarent, acquired by J&J, EndoMatrix, acquired by C.R. Bard & TransVascular, acquired by Medtronic. Other ExploraMed/NEA ventures include Moximed, Nuelle and Willow. Josh is currently also working with NEA where he is a General Partner on their healthcare team leading the medtech/healthtech practice. Josh serves on the board of Setpoint Medical, DOTS Technologies, Eargo, ExploraMed, Intrinsic Therapeutics, Moximed, Willow and Coravin. Josh holds over 300 patents and patent applications. He received an MBA from Columbia University, an MD from the NYU School of Medicine, a bachelor’s degree in Mechanical Engineering from MIT and is a Member of the College of Fellows of The American Institute for Medical and Biological Engineering and was awarded the Coulter Award for Healthcare Innovation by the Biomedical Engineering Society in 2018.

  • David J. Maron

    David J. Maron

    Clinical Professor, Medicine - Cardiovascular Medicine

    Current Research and Scholarly Interests Dr. Maron is the Co-Chair and Principal Investigator of the ISCHEMIA trial, and Co-Chair of the ISCHEMIA-CKD trial. These large, international, NIH-funded studies will determine whether an initial invasive strategy of cardiac catheterization and revascularization plus optimal medical therapy will reduce cardiovascular events in patients with and without chronic kidney disease and at least moderate ischemia compared to an initial conservative strategy of optimal medical therapy alone.

  • Michael V. McConnell, MD, MSEE

    Michael V. McConnell, MD, MSEE

    Clinical Professor, Medicine - Cardiovascular Medicine

    Current Research and Scholarly Interests My imaging research has involved clinical and molecular Imaging of cardiovascular disease, with a focus on coronary and vascular diseases, including atherosclerosis, aortic aneurysms, and vascular inflammation.

    My prevention research has involved innovative technologies to reduce coronary and vascular disease, including early disease detection plus leveraging mobile health to enhance heart-healthy activities in patients and populations.

  • Mark Mercola

    Mark Mercola

    Professor of Medicine (Cardiovascular)

    Bio Dr. Mercola is Professor of Medicine and Professor in the Stanford Cardiovascular Institute. He completed postdoctoral training at the Dana-Farber Cancer Institute and Harvard Medical School, was on the faculty in the Department of Cell Biology at Harvard Medical School for 12 years, and later at the Sanford-Burnham-Prebys Institute and Department of Bioengineering at the University of California, San Diego before relocating to Stanford in 2015.

    Prof. Mercola is known for identifying many of the factors that are responsible for inducing and forming the heart, including the discovery that Wnt inhibition is a critical step in cardiogenesis that provided the conceptual basis and reagents for the large-scale production of cardiovascular tissues from pluripotent stem cells. He has collaborated with medicinal chemists, optical engineers and software developers to pioneer the use of patient iPSC-cardiomyocytes for disease modeling, safety pharmacology and drug development. His academic research is focused on developing and using quantitative assays of patient-specific cardiomyocyte function to discover druggable targets for preserving contractile function in heart failure and promoting regeneration following ischemic injury. He co-established drug screening and assay development at the Conrad Prebys Drug Discovery Center (San Diego), which operated as one of 4 large screening centers of the US National Institutes of Health (NIH) Molecular Libraries screening initiative and continues as one of the largest academic drug screening centers.

    Prof. Mercola received an NIH MERIT award for his work on heart formation, and authored over 130 papers. He holds numerous patents, including describing the invention of the first engineered dominant negative protein and small molecules for stem cell and cancer applications. He serves on multiple editorial and advisory boards, including Vala Sciences,, Regencor, The Ted Rogers Centre for Heart Research and the Human Biomolecular Research Institute. His laboratory is funded by the NIH, California Institute for Regenerative Medicine and the Fondation Leducq.

  • Kegan Moneghetti MBBS (hons), FRACP, PhD

    Kegan Moneghetti MBBS (hons), FRACP, PhD

    Clinical Assistant Professor, Medicine - Cardiovascular Medicine

    Bio I am a cardiologist and researcher with specialty interests in sports medicine, heart failure and exercise testing. My background includes clinical training in internal medicine and cardiology through the Royal Australasian College of Physicians. I have completed an advance cardiac imaging fellowship (Monash Heart) and a post doctoral fellowship in exercise physiology (Stanford University). I have a clinical interest cardiovascular health in those wanting to be active or who regularly exercise (athletes and non-athletes). My current research projects are aimed at defining inflammasome/metabolic pathways with exercise and optimizing the use of demographic data to predict exercise performance in healthy individuals and those with heart failure.